South Korea produces world-class health AI, but many startups struggle to scale in Europe. In a recent interview with Korea Biomedical Review, Jason Hill, our AI and strategy lead explains why great tech isn't enough to close a deal.
The Main Takeaways:
-
Local Proof is Key: Success in Seoul doesn’t automatically translate to trust in Helsinki. European buyers need evidence that mirrors their own clinical systems.
-
What changes on Monday morning? Hospitals don’t care about flashy demos; they care about how the tool changes daily workflow the moment it goes live.
-
Beyond the CE Mark: Regulatory clearance is only the beginning. Buyers prioritize clinical accountability, data privacy, and long-term risk management.
-
Value in the Dull Work: The biggest demand isn’t for complex diagnostics, but for AI that automates boring day to day bottlenecks like documentation and triage to ease staffing shortages.
The Bottom Line: To win in Europe, startups must pivot from polishing their algorithms to mastering local business development and clinical integration.
Want the full story? For the deep dive into the specific hurdles and opportunities in the European market, read the full article at Korea Biomedical Review.
